Lifirafenib maleate is under clinical development by BeiGene and currently in Phase II for Thyroid Cancer. According to GlobalData, Phase II drugs for Thyroid Cancer have a 45% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Lifirafenib maleate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Lifirafenib maleate overview
Lifirafenib maleate is under development for the treatment of solid tumors like BRAF and non-BRAF mutated melanoma, thyroid cancer, ovarian cancer, endometrial cancer, colorectal cancer, pancreatic cancer, cholangiocarcinoma and non-small cell lung cancer. The drug candidate is administered orally. It targets both epidermal growth factor receptor (EGFR) and B-RAF kinase.
BeiGene is a biotechnology company. It is specialized in the development and commercialization of immuno-oncology medicines to treat cancers. The company offers BRUKINSA, a BTK (Bruton’s tyrosine kinase) inhibitor against mantle cell lymphoma (MCL). BeiGene is investigating Zanubrutinib (BGB-3111), a small molecule inhibitor of BTK to treat B cell malignancies; Tislelizumab (BGB-A317), a monoclonal antibody targeting solid tumors and hematologic cancer; and Pamiparib (BGB-290) against solid tumor malignancies. It seeks to work in partnership with academia, biotechnology and pharmaceutical companies to develop treatments for cancer patients. The company has operations in the US, Australia, Germany, Spain Switzerland, and Italy. BeiGene is headquartered in Beijing, China.
For a complete picture of Lifirafenib maleate’s drug-specific PTSR and LoA scores, buy the report here.